Clinical and Observational Trials
-
Principal Investigator:
June Y. Hou, MD
In this research study, an investigational medication named ACR-368 (also known as prexasertib) is being tested for the treatment of ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma. In this study, ACR-368 is being tested when it is given alone (called monotherapy) and when it is combined with low doses of a chemotherapy medication named gemcitabine (called combination therapy). ACR-368 has not been approved for use as a treatment for any condition, by government agencies in any country. ACR-368 is a type of medication called a checkpoint kinase inhibitor which may...
-
Principal Investigator:
June Y. Hou, MD
This research study has two parts. Participants will be enrolled in the second part of the study. The names of the study drugs are RGX-104, nivolumab, ipilimumab, docetaxel, carboplatin, and pemetrexed. The purpose of the first part of the study is to determine the highest dose of RGX-104 the body can handle. The purpose of the second part is to determine if the highest dose of RGX-104 determined in the first part might be an effective treatment option for people with advanced cancers. Both parts of the study will try to understand the safety and side effects of RGX-104.
-
Principal Investigator:
S. Zev Williams, MD, PhD
Researchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation.
-
Principal Investigator:
June Y. Hou, MD
The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
-
Principal Investigator:
June Y. Hou, MD
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself SOC chemotherapy, or experimental drug called TransCon TLR7/8 Agonist, or in combination with SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of cancer cells. The study drugs TransCon IL-2 / and TransCon TLR7/8 Agonist (TLR7/8) have not been approved by the Food and Drug Administration FDA for your type of cancer. We also want to find a dose of TransCon IL-2 / that is safe and tolerable for adult patients who...
-
Principal Investigator:
Paula M Castaño, MD, MPH
The study is looking to evaluate levonogestrel butanoate as a possible new long-acting injectable for birth control. Levonogestrel butanoate is a type of hormone called progestin that has a long history of clinical use in a variety of birth control methods (e.g. pills, intrauterine devices, implants) and its efficacy and safety are well recognized. This study is seeking for healthy female volunteers between the ages of 18-40 years of age. Participation time is estimated to last up to 9 months with approximately 36 study visits. The first visit will last about 1 hour and all other visits will...
-
Principal Investigator:
Jason D. Wright, MD
The purpose of this study is to collect vaginal, cervical, and uterine samples for the study during your scheduled surgery. The samples will be collected using cell collection tools similar to how samples are collected during your regular pelvic exams, such as a pap smear to develop a collection method for endometrial sampling which is less invasive and less painful than the current sampling method and develop a test which can be used to identify those patients who are benign for uterine cancer with similar accuracy as current diagnostic methods. This could greatly reduce the patients...
Pages
